Cognitive-Based Balance Rehabilitation in Parkinson's Disease: Virtual Reality vs. Dual Task
2026년 6월 23일 업데이트: Bezmialem Vakif University
Effects of Cognitive-Based Balance Rehabilitation on Balance, Gait and Cognitive Functions in Parkinson's Disease Patients: Comparison of Virtual Reality and Dual Task
This prospective, randomized, single-blind, controlled clinical trial aims to evaluate and compare the efficacy of cognitive-based balance rehabilitation delivered via immersive Virtual Reality (VR) versus traditional Dual-Task Training (DTT) on balance, gait, cognitive functions, and quality of life in patients with Parkinson's Disease (PD).
Postural instability and cognitive decline are hallmark features of progressive PD that significantly elevate fall risks and compromise daily independence, yet conventional pharmacological therapies offer limited effectiveness in restoring complex postural control.
Given that motor and cognitive processes are intrinsically linked, this study addresses a critical gap in neurorehabilitation by investigating two contemporary modalities designed to challenge these systems simultaneously.
A total of 34 participants diagnosed with PD (aged 40-80 years, Hoehn and Yahr stages I-III) will be randomly allocated to either the Dual-Task Group (DTG), receiving structured therapeutic exercises integrated with sequential cognitive tasks, or the Virtual Reality Group (VRG), engaging in an immersive balance program utilizing the Oculus Quest 2® headset with the FIT-XR application.
Both groups will undergo an identical intervention protocol consisting of 45-minute supervised sessions, conducted twice weekly for 8 consecutive weeks during their pharmacological "on" phase.
Standardized assessments will be performed by a blinded clinician at baseline and post-intervention (Week 8).
The primary outcome measures will be dynamic balance and gait assessed through the Mini-Balance Evaluations Systems Test (Mini-BESTest) alongside global cognitive performance measured via the Montreal Cognitive Assessment (MoCA).
Secondary outcomes will encompass objective posturographic indices using the Biodex Balance System, motor severity via the Unified Parkinson's Disease Rating Scale (UPDRS-III), freezing of gait, health-related quality of life, global perceived improvement, and potential cyber-sickness symptoms monitored through the Virtual Reality Sickness Questionnaire (VRSQ) to comprehensively determine the safety and comparative therapeutic value of these interventions.
연구 개요
상태
상태
아직 모집하지 않음
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
중재적
등록 (추정된)
등록
34
단계
단계
- 해당 없음
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
아니
설명
Inclusion Criteria:
- Diagnosed with Parkinson's Disease by a neurologist.
- Hoehn & Yahr Stage I-III.
- Aged between 40-80 years.
- Literate and capable of performing basic mathematical calculations.
- Montreal Cognitive Assessment≥21
- Stable pharmacological treatment.
- Physician's approval for exercise participation.
Exclusion Criteria:
- Currently participating in another exercise or drug trial.
- Presence of any additional neurological disorders.
- Significant musculoskeletal disorders, arthritis, or cardiovascular disease.
- Uncontrolled epilepsy or severe orthostatic hypotension.
- Engaged in regular moderate-intensity exercise more than once a week in the last 6 months.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
팔의 수
2
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
활성 비교기: Dual Task Group
Participants in this group will undergo a supervised, structured therapeutic exercise program specifically designed for balance and postural control, which will be integrated with concurrent, increasingly complex cognitive tasks (such as counting backward, calculation, or memory retrieval).
The intervention will consist of 45-minute sessions held twice a week for 8 consecutive weeks, totaling 16 sessions.
All exercises will be conducted by a physiotherapist during the patients' pharmacological 'on' phase.
|
A supervised physical therapy program consisting of motor balance and postural control exercises executed simultaneously with secondary cognitive tasks.
The physical component includes progressive static and dynamic balance training, functional gait training, and coordination exercises.
The concurrent cognitive tasks involve backward counting, mental arithmetic, and working memory retrieval.
The intervention is delivered in 45-minute sessions, twice a week for 8 weeks (16 sessions total) by a certified physiotherapist.
|
|
활성 비교기: Virtual Reality Group
Participants in this group will engage in an immersive Virtual Reality (VR) balance rehabilitation program utilizing the Oculus Quest 3® headset.
They will play the clinically validated FIT-XR application, which is tailored to target upper and lower extremity coordinate functions and dynamic balance.
The exercise intensity, session duration (45 minutes), and frequency (twice a week for 8 weeks, totaling 16 sessions) will be identical to the Dual Task Group.
Sessions will be supervised by a physiotherapist during the patients' pharmacological 'on' phase, with full safety protocols implemented to prevent fall risks.
|
An immersive virtual reality rehabilitation program utilizing the Oculus Quest 3® VR headset.
Participants engage in motion-based exercises within the clinically validated FIT-XR software application, specifically targeting multi-directional reaching, stepping, upper and lower limb coordination, and dynamic weight shifting.
The exercise intensity, session duration (45 minutes), and frequency (twice weekly for 8 weeks, 16 sessions total) are tightly matched to the Dual Task Group.
All sessions are fully supervised by a physiotherapist with standard safety measures.
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Mini-Balance Evaluations Systems Test
기간: Baseline and Week 8
|
A 14-item clinical rating scale specifically focused on dynamic gait and postural control across four domains: anticipatory postural adjustments, reactive postural responses, sensory orientation, and dynamic gait.
Each item is scored on a scale from 0 (unable to perform) to 2 (normal performance).
The total score ranges from 0 to 28, where higher scores indicate better dynamic balance and superior postural performance.
|
Baseline and Week 8
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Montreal Cognitive Assessment
기간: Baseline and Week 8
|
A 30-point screening instrument designed to detect mild cognitive impairment and dementia by evaluating short-term memory, visuospatial abilities, executive function, language, attention, concentration, working memory, and orientation.
The total score ranges from 0 to 30, with higher scores indicating better global cognitive function.
|
Baseline and Week 8
|
|
Biodex Balance System
기간: Baseline and Week 8
|
Postural stability (anterior-posterior stability index, mediolateral stability index, general stability index), fall risk index, and limits of stability will be assessed using the Biodex Balance System.
Higher scores on stability indices indicate poorer postural stability, while higher scores on limits of stability indicate better postural control.
|
Baseline and Week 8
|
|
Unified Parkinson's Disease Rating Scale - Part III (Motor Examination)
기간: Baseline and Week 8
|
A comprehensive clinical rating scale used to evaluate the severity of motor symptoms in Parkinson's disease.
Part III involves the objective motor examination.
Each item is scored from 0 (unaffected) to 4 (most severely affected), yielding a total score ranging from 0 to 108.
Higher scores indicate greater disease severity and more pronounced motor impairment.
|
Baseline and Week 8
|
|
Parkinson's Disease Questionnaire-39
기간: Baseline and Week 8
|
A 39-item self-administered, disease-specific health status instrument evaluating quality of life across 8 dimensions.
Each item is scored on a scale from 0 (never) to 4 (always).
Individual dimension scores and the global index are standardized to range from 0 to 100.
Higher scores indicate worse quality of life (more frequent difficulties), while lower scores reflect better health status.
|
Baseline and Week 8
|
|
Freezing of Gait Questionnaire
기간: Baseline and Week 8
|
A 6-item self-report questionnaire designed to evaluate the severity of freezing of gait and its impact on walking performance.
It includes 4 items on freezing severity and 2 items on general walking difficulty, with each item scored from 0 to 4. The total score ranges from 0 to 24, where higher scores indicate more severe freezing of gait and a greater negative impact on gait performance.
|
Baseline and Week 8
|
|
Global Rating of Change Scale
기간: Post-intervention (Week 8)
|
A 5-point Likert scale used to measure participants' subjective perception of overall health change and treatment satisfaction over the course of the study.
Total scores range from -2 to +2, where -2 represents "much worse", 0 represents "the same", and +2 represents "much better".
Higher scores indicate greater perceived improvement and higher treatment satisfaction.
|
Post-intervention (Week 8)
|
|
Virtual Reality Sickness Questionnaire
기간: Post-intervention (Week 8)
|
A 9-item self-report questionnaire assessing general oculomotor discomfort and disorientation following the virtual reality intervention.
Items are scored using a 4-point Likert scale from 0 (none) to 3 (severe).
The total score ranges from 0 to 27, where higher scores indicate worse and more severe cyber-sickness symptoms.
This measure is evaluated only for the Virtual Reality Group.
|
Post-intervention (Week 8)
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (추정된)
연구 시작
2026년 6월 20일
기본 완료 (추정된)
기본 완료
2027년 6월 30일
연구 완료 (추정된)
연구 완료
2027년 12월 30일
연구 등록 날짜
최초 제출
최초 제출
2026년 6월 16일
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
2026년 6월 16일
처음 게시됨 (실제)
처음 게시됨
2026년 6월 22일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
2026년 6월 25일
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
2026년 6월 23일
마지막으로 확인됨
마지막으로 확인됨
2026년 6월 1일
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- E-35700536-108.99-176309
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
아니
미국 FDA 규제 기기 제품 연구
아니
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .